首页>
外国专利>
COMBINATION THERAPY FOR NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS
COMBINATION THERAPY FOR NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS
展开▼
机译:壬酸脂肪肝(NASH)和肝纤维化的联合治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
The innovation is directed to a method for treating a CCR5 and/or CCR2 mediated disease such as nonalcoholic steatohepatitis (NASH) comprising administering an effective amount of a C-C Chemokine receptor 5 (CCR5) antagonist (e.g., maraviroc or vicriviroc or cenicriviroc) and/or an effective amount of a C-C Chemokine receptor 2 (CCR2) antagonist, or a CCR5/CCR2 antagonist together with an effective amount of farnesoid X receptor (FXR) agonist (e.g., obeticholic acid (OCA)). An "effective amount" can be a regular clinical dose of either agent alone or a reduced dose of the FXR receptor agonist and/or the CCR5/CCR2 antagonist. The combination is effective to treat NASH with (1) enhanced efficacy and (2) substantial reduction of side effects, particularly those associated with administration of OCA or its analogues, namely less effect on liver enzyme elevation, and less severity and frequency of pruritus (3). The fixed dose combination provides for better efficacy and safety profile.
展开▼